The research of Sanghuangporusbaumii tablets on immune regulation of colorectal cancer patients after chemotherapy

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100049792

Enrollment

Unknown

Registered

2021-08-09

Start date

2021-08-01

Completion date

Unknown

Last updated

2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer

Interventions

Experimental group:OralSanghuangporusbaumii tablets (15g per person per day, 200ml of boiling water for 15min, filter out the supernatant, then 200ml of boiling water for 15min, filter out the superna

Positive control group:The patient was treated with thymofaxine (1.6 mg subcutaneously twice a week) for 2 consecutive weeks.

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Colorectal cancer patients (TNM stage III-IV); 2. Those who are suitable for chemotherapy (the chemotherapy regimen is not limited), and patients with impaired immunity after chemotherapy (the ratio of CD4/CD8 in peripheral blood 6 months.

Exclusion criteria

Exclusion criteria: 1. Those with primary immunodeficiency disease and other serious infectious diseases, 2. Patients who have received immunomodulatory therapy before; 3. Patients with abnormal blood routine, liver function and renal function; 4. Pregnant or lactating women, and persons with mental disorders; 5. Those with poor compliance are easily lost to the follow-up.

Design outcomes

Primary

Measure	Time frame
Immunocompromised control ratio;Immune function index;Adverse reactions;Symptom score;	—

Countries

China

Contacts

Public ContactLi Ping

The First Affiliated Hospital of Anhui Medical University

1964liping@sina.com+86 13965112719

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026